Cargando…
Curcumin as an Adjuvant to Cancer Immunotherapy
The components of the immune system play a very sincere and crucial role in combating tumors. However, despite their firm efforts of elimination, tumor cells cleverly escape the surveillance process by adopting several immune evasion mechanisms. The conversion of immunogenicity of tumor microenviron...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415504/ https://www.ncbi.nlm.nih.gov/pubmed/34485117 http://dx.doi.org/10.3389/fonc.2021.675923 |
_version_ | 1783747981079478272 |
---|---|
author | Paul, Silpita Sa, Gaurisankar |
author_facet | Paul, Silpita Sa, Gaurisankar |
author_sort | Paul, Silpita |
collection | PubMed |
description | The components of the immune system play a very sincere and crucial role in combating tumors. However, despite their firm efforts of elimination, tumor cells cleverly escape the surveillance process by adopting several immune evasion mechanisms. The conversion of immunogenicity of tumor microenvironment into tolerogenic is considered as a prime reason for tumor immune escape. Therapeutically, different immunotherapies have been adopted to block such immune escaping routes along with better clinical outcomes. Still, the therapies are haunted by several drawbacks. Over time, curcumin has been considered as a potential anti-cancer molecule. Its potentialities have been recorded against the standard hallmarks of cancer such as continuous proliferation, escaping apoptosis, continuous angiogenesis, insensitivity to growth inhibitors, tissue invasion, and metastasis. Hence, the diversity of curcumin functioning has already been established and exploration of its application with immunotherapies might open up a new avenue for scientists and clinicians. In this review, we briefly discuss the tumor’s way of immune escaping, followed by various modern immunotherapies that have been used to encounter the escaping paths and their minute flaws. Finally, the conclusion has been drawn with the application of curcumin as a potential immune-adjuvant, which fearlessly could be used with immunotherapies for best outcomes. |
format | Online Article Text |
id | pubmed-8415504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84155042021-09-04 Curcumin as an Adjuvant to Cancer Immunotherapy Paul, Silpita Sa, Gaurisankar Front Oncol Oncology The components of the immune system play a very sincere and crucial role in combating tumors. However, despite their firm efforts of elimination, tumor cells cleverly escape the surveillance process by adopting several immune evasion mechanisms. The conversion of immunogenicity of tumor microenvironment into tolerogenic is considered as a prime reason for tumor immune escape. Therapeutically, different immunotherapies have been adopted to block such immune escaping routes along with better clinical outcomes. Still, the therapies are haunted by several drawbacks. Over time, curcumin has been considered as a potential anti-cancer molecule. Its potentialities have been recorded against the standard hallmarks of cancer such as continuous proliferation, escaping apoptosis, continuous angiogenesis, insensitivity to growth inhibitors, tissue invasion, and metastasis. Hence, the diversity of curcumin functioning has already been established and exploration of its application with immunotherapies might open up a new avenue for scientists and clinicians. In this review, we briefly discuss the tumor’s way of immune escaping, followed by various modern immunotherapies that have been used to encounter the escaping paths and their minute flaws. Finally, the conclusion has been drawn with the application of curcumin as a potential immune-adjuvant, which fearlessly could be used with immunotherapies for best outcomes. Frontiers Media S.A. 2021-08-16 /pmc/articles/PMC8415504/ /pubmed/34485117 http://dx.doi.org/10.3389/fonc.2021.675923 Text en Copyright © 2021 Paul and Sa https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Paul, Silpita Sa, Gaurisankar Curcumin as an Adjuvant to Cancer Immunotherapy |
title | Curcumin as an Adjuvant to Cancer Immunotherapy |
title_full | Curcumin as an Adjuvant to Cancer Immunotherapy |
title_fullStr | Curcumin as an Adjuvant to Cancer Immunotherapy |
title_full_unstemmed | Curcumin as an Adjuvant to Cancer Immunotherapy |
title_short | Curcumin as an Adjuvant to Cancer Immunotherapy |
title_sort | curcumin as an adjuvant to cancer immunotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415504/ https://www.ncbi.nlm.nih.gov/pubmed/34485117 http://dx.doi.org/10.3389/fonc.2021.675923 |
work_keys_str_mv | AT paulsilpita curcuminasanadjuvanttocancerimmunotherapy AT sagaurisankar curcuminasanadjuvanttocancerimmunotherapy |